|Bid||0.0000 x 47300|
|Ask||0.2900 x 1200|
|Day's Range||0.2400 - 0.2432|
|52 Week Range||0.2200 - 3.0000|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
The San Diego-based company said it had a loss of 18 cents per share. The developer of cell therapies posted revenue of $703,000 in the period. In the final minutes of trading on Tuesday, the company's ...
SAN DIEGO, May 14, 2019 -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q1 2019 financial results and provided updates on corporate.
Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced a transaction to divest certain cell therapy assets to Seijirō Shirahama of Tokyo, Japan yielding $3MM in non-dilutive funding to the Company, before related transaction expenses. “This cell therapy asset sale strengthens the company’s ability to achieve a number of important objectives including – enabling us to focus on our clinical stage oncology pipeline while bringing in additional non-dilutive capital,” said Dr. Marc Hedrick, Cytori President & Chief Executive Officer. This announcement follows an April 1, 2019 announcement stating that Cytori was to divest certain cell therapy assets to Lorem Vascular of Melbourne, Australia yielding $4MM in non-dilutive funding to the Company, before related transaction expenses.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Cytori Therapeutics, Inc.'s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidi...
On a per-share basis, the San Diego-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring gains, came to 20 cents per share. The developer of cell therapies posted revenue of ...
Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM Letter of intent for ATI-0918 filed with EMEA.
SAN DIEGO, March 29, 2019 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year-end financial results and business update on.
Cytori Therapeutics, Inc. (CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA’s centralized approval procedure. In addition, in late 2018, the EMA CHMP Name Review Group validated Doxorubicin Hydrochloride Cytori as the official invented name to replace ATI-0918. Doxorubicin Hydrochloride Cytori is a liposomal nanoparticle medicinal product being developed for cancer patients that contains the active substance doxorubicin, a widely used chemotherapy drug. Doxorubicin Hydrochloride Cytori is intended for the treatment of breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma.
Cytori Therapeutics, Inc. (CYTX) announces the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of refractory perianal fistula in patients with Crohn’s Disease. 10 patients were treated with a single administration of Cytori Cell Therapy™.
If you own shares in Cytori Therapeutics, Inc. (NASDAQ:CYTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
Cytori announced it has received approval for its Cellution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Cellution Cell Therapy System is a medical device designed to automate processing of adipose tissue to obtain regenerative cells suitable for treating thermal and radioactive burn wounds.
Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced that the Company has received approval for the Celution Cell Therapy System consumable bundle in Japan as a Class III medical device. The Class III designation will allow Cytori to expand its current commercial efforts in Japan and provides a clear framework for future expanded regulatory claims and reimbursement under the November 2014 PMD Act. Furthermore, Cytori announced today that the Company has successfully outsourced an important assembly portion of the production process for its Celution Cell Therapy consumables from San Diego, CA to Viant Medical in San Antonio, Texas.
Cytori (CYTX) delivered earnings and revenue surprises of -246.15% and -59.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 55 cents. Losses, adjusted for one-time items, came to 45 cents per share. The developer of cell therapies posted revenue of $1.3 ...
SAN DIEGO, Nov. 14, 2018 -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q3 2018 financial results and provided updates on corporate.
SAN DIEGO, Nov. 09, 2018 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday,.
Cytori Therapeutics, Inc. (CYTX) announced today it has received a milestone payment of $1.0 million from Bimini Technologies, LLC (Bimini). The payment is a result of Bimini achieving the first $10.0 million in gross profits for previous divestiture of the Puregraft® product line. In 2013, Cytori entered into a Sale and Exclusive License/Supply Agreement with Bimini, pursuant to which Cytori sold to Bimini selected assets relating to Cytori’s Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring.
Cytori Therapeutics Inc’s (NASDAQ:CYTX): Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical Read More...